Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-07-25
2009-12-01
Chernyshev, Olga N. (Department: 1649)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S325000, C435S007200, C435S007210, C435S069100, C530S350000, C514S001000, C977S716000
Reexamination Certificate
active
07625718
ABSTRACT:
SVCT2 is consistently expressed at high levels in brain microvessel endothelial cells. Disclosed herein are assays for determining whether a test material/molecule is a substrate for, and/or is actively transported by, the SVCT2 transporter, and therefore a candidate substrate for crossing the blood brain barrier. The assays are useful in screening for therapeutic, cytotoxic or imaging compounds used in the treatment or diagnosis of neurological diseases.
REFERENCES:
patent: 6489302 (2002-12-01), Wiessler et al.
patent: 2004/0006019 (2004-01-01), Hediger
patent: 2004/0197272 (2004-10-01), Fischer et al.
Daruwala et al. FEBS Letters, 460: 480-484, 1999.
Dalpiaz, Alessandro et al.; “Ascorbic and 6-Br-ascorbic acid conjugates as a tool to increase the therapeutic effects of potentially central active drugs”; 2005,European Journal of Pharmaceutical Sciences, vol. 24, pp. 259-269.
Manfredini, Stefano et al.; “Design, Synthesis and Activity of Ascorbic Acid Prodrugs of Nipecotic, Kynurenic and Diclophenamic Acids, Liable to Increase Neurotropic Activity”; 2002,J. Med. Chem., vol. 45, pp. 559-562.
Alderman, D. A., “A review of cellulose ethers in hydrophilic matricies for oral controlled-release dosage forms,”Int. J. Pharm. Tech. &Prod. Mfr., 5(3):1-9 (1984).
Altschul et al., “Basic Local Alignment Search tool,”J. Mol. Biol., 215:403-410 (1990).
Audus et al., “The use of cultured epithelial and endothelial cells for drug transport and metabolism studies,”Pharm. Res., 7:435-451 (1990).
Audus et al., “Characterization of an in vitro blood-brain barrier model system for studying drug transport and metabolism,”Pharm. Res., 3:81-87 (1986).
Bamba et al., “Release mechanisms in gelforming sustained release preparations,”Int. J. Pharm., 2:307-315 (1979).
Bowman et al., “Brain microvessel endothelial cells in tissue culture: A model for study of blood-brain barrier permeability,”Ann. Neurol., 14:396-402 (1983).
Controlled Drug Bioavailability, vol. 1, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984).
Cserr et al., “Blood-brain interfaces in vertebrates: a comparative approach,”Am. J. Physiol. Regul. Integr. Comp. physiol., 246, R277-R288 (1984).
During et al., “Controlled Release of Dopamine from a Polymeric Brain Implant: In Vivo Characterization,” 1989,Ann. Neurol, 25:351-356 (1989).
Goldstein et al. “The Blood-Brain Barrier,”Scientific American, 255:74-83 (1986).
Hanes et al., “New Advances in Microsphere-based single-dose vaccines,”Advanced Drug Delivery Reviews, 28:97-119 (1997).
Henikoff et al., “Amino acid substitution matricies from protein blocks,”PNAS, 89:10915-10919 (1989).
Howard et al., “Intracerebral drug delivery in rats with lesion-induced memory deficits,”J. Neurosurg., 71:105-112 (1989).
Karlin et al., “Applications and statistics for multiple high -scoring segments in molecular sequences,”PNAS, 90:5873-5787 (1993).
Langer et al., “Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review,”JMS-REV. Macromol. Chem. Phys., C23(1):61-126 (1983).
Langer, R., “New Methods of Drug Delivery,”Science, 249:1527-1533 (1990).
Levy et al., “Inhibition of Calcification of Bioprosthetic Heart valves by Local Controlled-Release Diphosphonate,”Science, 228:190-192 (1985).
Masereeuw et al., “In vitro and in vivo transport of zidovudine (AZT) across the blood-brain barrier and the effect of transport inhibitors,”Pharm. Res., 11(2):324-330 (1994).
Medical Applications of Controlled Release, Langer and Wise (eds.), cover page and table of contents, CRC Pres., Boca Raton, Florida (1974).
Meresse et al., “Bovine brain endothelial cells express tight junctions and monoamine oxidase activity in long-term culture,”J. Neuorchem., 53:1363-1371 (1989).
Needleman et al., “A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins,”J. Mol. Biol., 48:443-453 (1970).
Neuwelt, eds.,Implications of the blood-brain barrier and its manipulation, vol. 1Basic Science Aspects, Plenum Medical, New York (1989).
Pardridge, W.M., “Receptor-Mediated Peptide Transport through the Blood-Brain Barrier,”Endocrin. Rev., 7(3):314-330 (1986).
Pardridge et al., “Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier,”J. Pharmacol. Exp. Thera., 253(2):884-891(1990).
Pearson et al., “Improved tools for biological sequence comparison,”PNAS, 85:24442448 (1988).
Remington's Pharmaceutical Sciences, Mace Publishing Company, Philadelphia, PA, 17th ed. (1985).
Smith et al., “Comparison of Biosequences,”Adv. Appl. Math., 2:482-489 (1981).
Terasaki et al., “New approaches to in vitro moidels of blood-brain barrier drug transport,”Drug Discovery Today, 8(20):944-954 (2003).
Tietz et al., “Fluorokinase abd Pyruvic Kinase,”Arch. Biochim. Biophys., 78:477-493 (1958).
Chernyshev Olga N.
MacFarlane Stacey
Townsend and Townsend / and Crew LLP
XenoPort, Inc.
LandOfFree
SVCT2 transporters expressed in blood brain barrier cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with SVCT2 transporters expressed in blood brain barrier cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and SVCT2 transporters expressed in blood brain barrier cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4082484